Safinamide (Xadago®) is a MAO-B inhibitor used as an add-on to levodopa in Parkinson’s disease, especially for patients with motor fluctuations or “off” episodes. It works by both inhibiting dopamine breakdown and modulating glutamate release, which may provide added benefit compared to older MAO-B inhibitors. Safinamide can help improve motor control and daily function, making levodopa’s effects last longer. Common side effects include dyskinesia, nausea, insomnia, and headache, though it is usually well tolerated. Its dual mechanism makes it a valuable option for patients needing more stable symptom control.